Binding of <i>PC3/Tis21</i> to the <i>Id3</i> promoter and corresponding decrease of <i>Id3</i> mRNA. by Stefano Farioli-Vecchioli (256006)

“…(<b>B</b>) ChIP analysis of <i>PC3</i> binding to the <i>Id3</i> promoter in PC12 cells, treated as shown in (<b>A</b>). A scheme above the graph describes the <i>Id3</i> gene and the promoter region analyzed, 700 nt 5′ to the transcription start. …”

Impact of deforestation and subsequent land-use diversity on active carbon (AC), fulvic acid (FA), humic acid (HA), and glucose equivalent total non-humic carbon (NH) lability indi... by Emmanuel Amoakwah (13228938)

Percentage decrease in the response time (mean ± std) in the post-training test phase when compared to that in the pre-training phase. by Lilian Fautrelle (711885)

PowerPoint Slides for: Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy by Xie X. (2945913)

“…It also significantly decreased plasma IgA-IgG complex levels (pre-PE: 85.3 ± 25.9% vs. post-PE: 38.4 ± 12.4%, p < 0.001) and plasma and urinary active complement product levels, including C3a, C5a and soluble C5b-9. …”

Effects of tolvaptan on brain water content (BWC), plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

Metalloproteinase gene expression at different time points expressed as ΔCt. by Fabíola S. Z. Robertoni (751356)

Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

“…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”

A Point Mutation in a Herpesvirus Polymerase Determines Neuropathogenicity by Laura B Goodman (80305)

Mice containing functional TSP-1 protein have decreased phagocytic capacity as compared to mice lacking functional TSP-1, and show increased survival in a non-surgical model of sepsis. by Sara McMaken (90003)

The optimization algorithm to identify ideal conditions for detection of epistasis is exemplified through the 3D scatter plot of three different measures of LD. by Gabriele Pedruzzi (5753792)

P-V Fit Scores Across Demographic Factors Among 636 residents. by Yaotian Fan (5917766)

Subjects:

S1 Graphical abstract - by Aman Goyal (19231397)

“…</p><p>Conclusions</p><p>Our analysis showed a significant decrease in mortality from paroxysmal tachycardia since 1999, although there has been a slight increase in recent years. …”

Supplementary Material for: MicroRNA-125a Correlates with Decreased Psoriasis Severity and Inflammation and Represses Keratinocyte Proliferation by Su F. (4127968)

<i>COX6C</i> promoter DNA methylation by MetS status. by Keane Urashima (11625020)

Subjects:

<i>RPL9</i> promoter DNA methylation by MetS status. by Keane Urashima (11625020)

Subjects:

Group means ± S.E. across standardised data for identified GC peaks grouped per biological group significantly varying according to the treatments. by Sergio Saia (529861)

PPM1A facilitates both nuclear distribution and transcription potency of YAP/TAZ. by Ruyuan Zhou (10197187)

“…<b>(B–D)</b> Transcription potency of YAP (5 ng), which was suppressed by coexpression of MST1 (50 ng) (B), LATS1 (500 ng) (C), or MAP4K1 (50 ng) (D), was markedly recovered by cotransfection of wild-type PPM1A but not the enzyme-dead PPM1A (D239N). …”

Reducing MALAT1 expression decreased fibrosis of NIH-3T3 and decreased the expression level of P2ry2. by Mengjie Chen (483583)

Conduction slowing at branching points. by Tanmay A. Gokhale (3687244)

“…An up to 36.6% decrease in local conduction velocity leads to a conduction delay across the branch point (middle panel) and a net 11.8% reduction in mean CV along the strand (bottom panel, dashed). …”

Diel activity patterns of deermice in each treatment (T). by André V. Rubio (4594702)